Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:21697469rdf:typepubmed:Citationlld:pubmed
pubmed-article:21697469lifeskim:mentionsumls-concept:C0000742lld:lifeskim
pubmed-article:21697469lifeskim:mentionsumls-concept:C1510411lld:lifeskim
pubmed-article:21697469lifeskim:mentionsumls-concept:C0021547lld:lifeskim
pubmed-article:21697469pubmed:issue17lld:pubmed
pubmed-article:21697469pubmed:dateCreated2011-8-9lld:pubmed
pubmed-article:21697469pubmed:abstractTextv-Abl protein tyrosine kinase encoded by Abelson murine leukemia virus (Ab-MLV) transforms pre-B cells. Transformation requires the phosphatidylinositol 3-kinase (PI3K) pathway. This pathway is antagonized by SH2-containing inositol 5'-phosphatase (SHIP), raising the possibility that v-Abl modulates PI3K signaling through SHIP. Consistent with this, we show that v-Abl expression reduces levels of full-length p145 SHIP in a v-Abl kinase activity-dependent fashion. This event requires signals from the Abl SH2 domain but not the carboxyl terminus. Forced expression of full-length SHIP significantly reduces Ab-MLV pre-B-cell transformation. Therefore, reduction of SHIP protein by v-Abl is a critical component in Ab-MLV transformation.lld:pubmed
pubmed-article:21697469pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21697469pubmed:languageenglld:pubmed
pubmed-article:21697469pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21697469pubmed:citationSubsetIMlld:pubmed
pubmed-article:21697469pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21697469pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21697469pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21697469pubmed:statusMEDLINElld:pubmed
pubmed-article:21697469pubmed:monthSeplld:pubmed
pubmed-article:21697469pubmed:issn1098-5514lld:pubmed
pubmed-article:21697469pubmed:authorpubmed-author:RosenbergNaom...lld:pubmed
pubmed-article:21697469pubmed:authorpubmed-author:FesslerShawn...lld:pubmed
pubmed-article:21697469pubmed:authorpubmed-author:BaughnLinda...lld:pubmed
pubmed-article:21697469pubmed:issnTypeElectroniclld:pubmed
pubmed-article:21697469pubmed:volume85lld:pubmed
pubmed-article:21697469pubmed:ownerNLMlld:pubmed
pubmed-article:21697469pubmed:authorsCompleteYlld:pubmed
pubmed-article:21697469pubmed:pagination9239-42lld:pubmed
pubmed-article:21697469pubmed:meshHeadingpubmed-meshheading:21697469...lld:pubmed
pubmed-article:21697469pubmed:meshHeadingpubmed-meshheading:21697469...lld:pubmed
pubmed-article:21697469pubmed:meshHeadingpubmed-meshheading:21697469...lld:pubmed
pubmed-article:21697469pubmed:meshHeadingpubmed-meshheading:21697469...lld:pubmed
pubmed-article:21697469pubmed:meshHeadingpubmed-meshheading:21697469...lld:pubmed
pubmed-article:21697469pubmed:meshHeadingpubmed-meshheading:21697469...lld:pubmed
pubmed-article:21697469pubmed:meshHeadingpubmed-meshheading:21697469...lld:pubmed
pubmed-article:21697469pubmed:meshHeadingpubmed-meshheading:21697469...lld:pubmed
pubmed-article:21697469pubmed:meshHeadingpubmed-meshheading:21697469...lld:pubmed
pubmed-article:21697469pubmed:year2011lld:pubmed
pubmed-article:21697469pubmed:articleTitleSH2-containing inositol 5'-phosphatase inhibits transformation of Abelson murine leukemia virus.lld:pubmed
pubmed-article:21697469pubmed:affiliationImmunology Graduate Program, Sackler School of Graduate Biomedical Sciences, Tufts University School of Medicine, Boston, Massachusetts 02111, USA.lld:pubmed
pubmed-article:21697469pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:21697469pubmed:publicationTypeResearch Support, N.I.H., Extramurallld:pubmed
entrez-gene:16331entrezgene:pubmedpubmed-article:21697469lld:entrezgene
entrez-gene:1491873entrezgene:pubmedpubmed-article:21697469lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:21697469lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:21697469lld:entrezgene